Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 40% and 16.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.40 (+15.25%)
ALIM : 3.59 (+1.41%)
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

ARQT : 8.74 (-2.24%)
CDXC : 3.40 (+15.25%)
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

CRSP : 56.41 (+1.35%)
CDXC : 3.40 (+15.25%)
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...

CDXC : 3.40 (+15.25%)
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.40 (+15.25%)
ICVX : 15.31 (-0.91%)
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

CDXC : 3.40 (+15.25%)
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners...

CDXC : 3.40 (+15.25%)
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANIP : 66.14 (+0.79%)
CDXC : 3.40 (+15.25%)
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDXC : 3.40 (+15.25%)
BNGO : 0.7944 (+4.44%)
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to...

CDXC : 3.40 (+15.25%)

Barchart Exclusives

Should You Buy This Beaten-Down AI Stock for Its 4% Dividend Yield?
Sales of AI-enabled gadgets are expected to drive hardware sales over the next few years. PC maker HP looks like an AI play worth buying for its nearly 4% dividend yield and tepid valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar